13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuroprogression
Neuroprogression denotes the gradual deterioration of symptoms and cognitive functions seen in various neurological disorders like Alzheimer's, Parkinson's, and multiple sclerosis (MS). It encapsulates the evolving structural and functional alterations within the brain, ultimately resulting in escalating disability and impairment in daily life. This phenomenon encompasses the progressive accumulation of neuronal damage, inflammation, and the loss of neural connections. In Alzheimer's, neuroprogression entails the progressive accumulation of amyloid plaques and tau protein tangles, leading to nerve cell degeneration and cognitive decline. Similarly, Parkinson's disease manifests as the gradual loss of dopamine-producing neurons in the substantia nigra, worsening motor symptoms like tremors and stiffness. In MS, immune attacks on the myelin sheath lead to scar tissue formation and progressive neurological dysfunction, including muscle weakness and coordination problems. Understanding neuroprogression is pivotal for devising effective treatments to slow or halt disease progression. Researchers explore various strategies, from targeted medications to lifestyle interventions and neurorehabilitation techniques, to mitigate neuroprogressive processes and enhance patients' quality of life. Early diagnosis, ongoing monitoring, and multidisciplinary care are vital for managing the complex needs of individuals with progressive neurological conditions.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States